Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hemogenyx PharmaceuticalsHOPHF 23 EV-to-EBITDA is -4.61 as of Aug. 23, 2026. GuruFocus rates HOPHF with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 407 Biotechnology companies, Hemogenyx Pharmaceuticals ranks worse than 245700% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hemogenyx Pharmaceuticals's enterprise value is $55.61 Mil.
Hemogenyx Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-12.06 Mil. Therefore, Hemogenyx Pharmaceuticals's EV-to-EBITDA for today is -4.61.
The historical rank and industry rank for Hemogenyx Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
HOPHF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.55 Med: 0 Max: 0
Current: -4.55
HOPHF's EV-to-EBITDA is ranked worse than 100% of 407
companies
in the Biotechnology industry
Industry Median: 14.17
vs HOPHF: -4.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hemogenyx Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Hemogenyx Pharmaceuticals's share price for today is $2.33.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hemogenyx Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.974.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOPHF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemogenyx Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hemogenyx Pharmaceuticals's EV-to-EBITDA falls into.
Hemogenyx Pharmaceuticals's current Enterprise Value is $55.61 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hemogenyx Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-12.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemogenyx Pharmaceuticals (HOPHF) has a EV-to-EBITDA of -4.61 as of Aug. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hemogenyx Pharmaceuticals. According to the industry distribution chart, Hemogenyx Pharmaceuticals ranks #999999 out of 407 companies in the Biotechnology industry.
Is Hemogenyx Pharmaceuticals' EV-to-EBITDA too high?
Hemogenyx Pharmaceuticals' current EV-to-EBITDA is -4.61. Based on the distribution chart, Hemogenyx Pharmaceuticals ranks #999999 out of 407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Hemogenyx Pharmaceuticals' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hemogenyx Pharmaceuticals ranks #999999 out of 407 companies for EV-to-EBITDA. This places Hemogenyx Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 14.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.17, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hemogenyx Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 14.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemogenyx Pharmaceuticals's current EV-to-EBITDA is -4.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemogenyx Pharmaceuticals stock overvalued right now?
Hemogenyx Pharmaceuticals (HOPHF) has a current EV-to-EBITDA of -4.61. The current EV-to-EBITDA is -4.61. Hemogenyx Pharmaceuticals' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (HOPHF), the current EV-to-EBITDA is -4.61 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
23GF Score
Get the complete analysis for HOPHF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOPHF has been successfully added to your 
